Siess W, Dray F
J Lab Clin Med. 1982 Mar;99(3):388-98.
Two stable derivatives of PGI2, its nonenzymatic hydrolysis product (6-keto-PGF1 alpha) and an enzymatic metabolite (6, 15-diketo-PGF1 alpha), were determined in human plasma and urine. These compounds were measured by RIA after separation on rp-HPLC. Previous purification of the samples on rp-HPLC markedly enhanced the specificity of the RIA determinations of those compounds in plasma and urine. The PGI2 derivative 6-keto-PGF1 alpha was detected in both plasma (4.7 +/- 3.2 pg/ml, mean +/- S.D., n=34) and urine (166 +/- 61 pg/ml, n=9). No gender differences of the plasma or urinary levels of 6-keto-PGF1 alpha were found. The PGI2 metabolite 6,15-diketo-PGF1 alpha was not measurable in plasma or urine (less than 1 and less than 10 pg/ml, respectively, n=4). Thus this compound may not be a major endogenous metabolite of PGI2 in man. When [3H]PGI2 was added to citrated blood immediately after venipuncture, it was recovered entirely as [3H]6-keto-PGF1 alpha after rp-HPLC. Therefore any circulating PGI2 would be measured as 6-keto-PGF1 alpha by our method. The results obtained suggest that PGI2 could be present in human venous blood under physiological conditions, but only in very low concentrations. (J Lab Clin Med 99:388, 1982.)
在人血浆和尿液中测定了前列环素（PGI2）的两种稳定衍生物，即其非酶促水解产物（6-酮-前列腺素F1α）和一种酶促代谢产物（6,15-二酮-前列腺素F1α）。这些化合物在反相高效液相色谱（rp-HPLC）上分离后，通过放射免疫分析（RIA）进行测定。先前在rp-HPLC上对样品进行纯化，显著提高了血浆和尿液中这些化合物RIA测定的特异性。在血浆（4.7±3.2 pg/ml，平均值±标准差，n = 34）和尿液（166±61 pg/ml，n = 9）中均检测到PGI2衍生物6-酮-前列腺素F1α。未发现6-酮-前列腺素F1α的血浆或尿液水平存在性别差异。PGI2代谢产物6,15-二酮-前列腺素F1α在血浆或尿液中无法检测到（分别小于1和小于10 pg/ml，n = 4）。因此，该化合物可能不是人体内PGI2的主要内源性代谢产物。静脉穿刺后立即将[3H]PGI2加入枸橼酸化血液中，经rp-HPLC分离后，它完全以[3H]6-酮-前列腺素F1α的形式回收。因此，通过我们的方法，任何循环中的PGI2都将被测定为6-酮-前列腺素F1α。所得结果表明，生理条件下PGI2可能存在于人体静脉血中，但浓度非常低。（《实验室与临床医学杂志》99:388, 1982.）
